These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 22300720)

  • 41. Global perspectives on vaccine financing.
    Berman S; Giffin RB
    Expert Rev Vaccines; 2004 Oct; 3(5):557-62. PubMed ID: 15485335
    [TBL] [Abstract][Full Text] [Related]  

  • 42. GAVI's Advance Market Commitment.
    Light DW
    Lancet; 2010 Feb; 375(9715):638. PubMed ID: 20171397
    [No Abstract]   [Full Text] [Related]  

  • 43. A theoretical flaw in the advance market commitment idea.
    Sonderholm J
    J Med Ethics; 2010 Jun; 36(6):339-43. PubMed ID: 20530089
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Conjugate pneumococcal vaccines and influence on the ear, nose and throat area].
    Almaç A; Kuru FD
    Kulak Burun Bogaz Ihtis Derg; 2011; 21(6):345-8. PubMed ID: 22014302
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
    Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
    Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chapter 26: Innovative financing mechanisms to accelerate the introduction of HPV vaccines in developing countries.
    Batson A; Meheus F; Brooke S
    Vaccine; 2006 Aug; 24 Suppl 3():S3/219-25. PubMed ID: 16950010
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Partnering for Vaccine Emerging Markets--Berlin, June 10-11, 2013: balancing vaccine quality, capacity, and cost-of-goods in emerging markets.
    Onraedt A
    Hum Vaccin Immunother; 2013 Sep; 9(9):2022-4. PubMed ID: 23966097
    [TBL] [Abstract][Full Text] [Related]  

  • 48. GAVI's Advance Market Commitment.
    Schwalbe N; El-Ziq I
    Lancet; 2010 Feb; 375(9715):638-9. PubMed ID: 20171398
    [No Abstract]   [Full Text] [Related]  

  • 49. Will biomedical innovation change the future of healthcare?
    Schmid EF; Ashkenazy R; Merson J; Smith DA
    Drug Discov Today; 2009 Nov; 14(21-22):1037-44. PubMed ID: 19647096
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A pharmacoeconomic evaluation of 7-valent pneumococcal conjugate vaccine in Canada.
    Lebel MH; Kellner JD; Ford-Jones EL; Hvidsten K; Wang EC; Ciuryla V; Arikian S; Casciano R
    Clin Infect Dis; 2003 Feb; 36(3):259-68. PubMed ID: 12539065
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Emerging issues in vaccine economics: perspectives from the USA.
    Lieu TA; Thompson KM; Prosser LA; O'Brien MA; Yusuf HR; Shefer AM; Weinstein MC; Rickert DL
    Expert Rev Vaccines; 2002 Dec; 1(4):433-42. PubMed ID: 12901581
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Economic evaluation of an infant immunization program in Mexico, based on 13-valent pneumococcal conjugated vaccines].
    Muciño-Ortega E; Mould-Quevedo JF; Farkouh R; Strutton D
    Value Health; 2011; 14(5 Suppl 1):S65-70. PubMed ID: 21839902
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Increase in invasive pneumococcal disease in children associated with shortage of heptavalent pneumococcal conjugate vaccine.
    Abuelreish M; Subedar A; Chiu T; Wludyka P; Rathore M
    Clin Pediatr (Phila); 2007 Jan; 46(1):45-52. PubMed ID: 17164509
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.
    Melegaro A; Edmunds WJ
    Vaccine; 2004 Oct; 22(31-32):4203-14. PubMed ID: 15474710
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Do we need a structural engineer to redesign our vaccine infrastructure?
    Berman S
    Pediatrics; 2003 Sep; 112(3 Pt 1):671-2. PubMed ID: 12949300
    [No Abstract]   [Full Text] [Related]  

  • 56. Indian vaccine innovation: the case of Shantha Biotechnics.
    Chakma J; Masum H; Perampaladas K; Heys J; Singer PA
    Global Health; 2011 Apr; 7():9. PubMed ID: 21507259
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Emerging vaccine manufacturers are innovating for the next decade.
    Hayman B; Pagliusi S
    Vaccine X; 2020 Aug; 5():100066. PubMed ID: 32462140
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Donors agree financial arrangement to stimulate vaccine development.
    Jack A
    BMJ; 2008 Apr; 336(7648):797. PubMed ID: 18403540
    [No Abstract]   [Full Text] [Related]  

  • 59. Charity urges drug firms to reduce price of pneumonia vaccine.
    Gulland A
    BMJ; 2015 Nov; 351():h6131. PubMed ID: 26566994
    [No Abstract]   [Full Text] [Related]  

  • 60. Refugees in South Sudan to receive pneumococcal vaccine after delays over price.
    Moszynski P
    BMJ; 2013 Aug; 347():f5042. PubMed ID: 23935063
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.